<DOC>
	<DOCNO>NCT02591290</DOCNO>
	<brief_summary>The aim study collect information regard increase immune response SP284 additional dose Japanese subject . Primary Objective : - To evaluate describe immune response meningococcal antigen ( serogroups A , C , Y W-135 ) 28 day follow vaccination SP284 vaccine subject 20 55 year age . Other Pre-specified objective : - To describe safety term immediate systemic adverse event , solicit reaction , unsolicited non-serious adverse event , serious adverse event ( SAEs ) follow receipt dose SP284 vaccine person 20 55 year age .</brief_summary>
	<brief_title>Immunogenicity Safety Two-Dose Series Menactra® Japanese Healthy Adult Subjects</brief_title>
	<detailed_description>All subject receive 2-dose series study vaccine 8-week interval monitor safety assess immunogenicity baseline ( pre-vaccination ) , 28 35 day post-1st 2nd vaccination , respectively .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 20 55 year day inclusion Informed consent form sign date subject Able attend schedule visit comply trial procedure For female subject childbearing potential , use effective method contraception least 4 week prior vaccination least 4 week vaccination ) `` 20 55 year '' mean day 20th birthday day 56th birthday . b ) To consider childbearing potential , woman must either undergone surgical sterilization ( hysterectomy bilateral tubal ligation ) postmenopausal ( least one year without menses ) time vaccination . Effective method contraception include oral contraception ( pill ) , intrauterine device , diaphragm condom use sponge , contraceptive foam cream , hormonal implant , transdermal patch , parenteral contraception . Chronic illness , opinion investigator , stage might interfere trial conduct completion History meningococcal disease , confirm either clinically , serologically , microbiologically Known systemic hypersensitivity vaccine component , history life threaten reaction vaccine contain substance study vaccine Known suspect congenital current/ previous acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial inclusion Planned participation another clinical trial present trial period Receipt immune globulin , blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine within four week precede trial vaccination , except influenza vaccination , may receive least two week study vaccine Planned receipt vaccine trial period Clinical known serological evidence systemic illness include Hepatitis B , Hepatitis C and/or Human Immunodeficiency Virus infection Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Known thrombocytopenia , contraindicate intramuscular ( IM ) vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator Previous vaccination meningococcal disease either trial vaccine another vaccine At high risk meningococcal infection trial Febrile illness ( temperature ≥ 37.5°C ) moderate severe acute illness/infection ( accord investigator judgment ) day vaccination . A prospective subject include study condition resolve febrile event subside Received oral inject antibiotic therapy within 72 hour prior blood draw ( Visit 1 ) History GuillainBarré Syndrome ( GBS ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Meningococcal Vaccine</keyword>
</DOC>